A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
Status: SUSPENDED
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: BIOLOGICAL: NeoTCR-P1 adoptive cell therapy|BIOLOGICAL: nivolumab|BIOLOGICAL: IL-2
Sponsor: PACT Pharma, Inc.